Cenrifki approved in EU for secondary progressive multiple sclerosis

▤ Summary

Sanofi has won EU approval for Cenrifki (tolebrutinib) for adults with non-relapsing secondary progressive multiple sclerosis. The approval makes it the first EU-authorized medicine aimed specifically at slowing disability progression in this patient group. Sanofi says the treatment showed a meaningful delay in disability progression in the HERCULES phase 3 study and will launch commercially in Germany later this year. The company will pair the rollout with medical team coordination, a risk management program, and a patient support program because liver monitoring is a key safety requirement.

▦ Linked Companies